Read more
3:08 PM · 13 July 2020

Quest Diagnostics stock rose 5.4% after its preliminary Q2 results

-
-
Open account Download free app
Quest Diagnostics (DGX.US) reported preliminary second-quarter revenue above analyst expectations, due largely to growing demand for Covid-19 tests. The medical lab operator expects second-quarter revenue of about $1.83 billion, a decline of about 6% from the year-earlier period but well ahead of the $1.53 billion FactSet consensus. Company expects per-share earnings of $1.33 to $1.36, compared with $1.51 a year ago. Adjusted EPS is expected to range from $1.39 to $1.42, compared with $1.73 in 2019 and a the FactSet estimates of 16 cents. Quest Diagnostics will report second-quarter earnings on July 23.
Quest Diagnostics (DGX.US)  has been trading in an sideways move since end of April. The price bounced off the lower limit of consolidation range at the end of June. Today, one can see that the upward move is being continued after US open. Currently stock is approaching the key resistance area at $123.57 per share. If sellers manage to halt declines here, the downward move into $102.92 per share is possible. Source: xStation5
11 March 2026, 4:40 PM

Rheinmetall earnings: Formidable growth, but the market expected more

11 March 2026, 3:43 PM

From Dependence to Control. Meta’s Development of Proprietary AI Chips

11 March 2026, 3:17 PM

Mixed sentiments on Wall Street amid Iran war🗽Oracle shares surge 10%

11 March 2026, 12:38 PM

Nebius shares surge 10% amid Nvidia $2 bln investment 📈

Join over 2 000 000 XTB Group Clients from around the world
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits